In the last 5 years, through combinatorial chemistry, high-throughput screening, computational chemistry, and traditional medicinal chemistry, numerous inhibitors for various protein tyrosine kinases (PTKs) have been developed. The majority of these compounds are small molecules that compete at the ATP binding site of the catalytic domain of the enzymes. Some compounds such as pseudosubstrate-based peptide inhibitor binds to the peptide/protein substrate site of the catalytic domain. Some inhibitors, primarily monoclonal antibodies, bind to the extracellular domain of receptor tyrosine kinases. Some of these inhibitors are highly potent and selective. Several are currently undergoing clinical trials for a number of diseases such as cancer. Oncogene (2000) 19, 5690 ± 5701.
Introduction
Protein tyrosine kinases (PTKs) are key enzymes in many signal transduction pathways and play a crucial role in many cell regulatory processes. Functional pertubation of some of the enzymes results in a variety of diseases (Hunter 1997; Patarca 1996; Kolibaba and Druker 1997) . Methods have been developed to evaluate the expression level of these enzymes in cell lines and tissues (Robinson et al., 1996) . It is estimated that there are over 2000 protein serine/threonine kinases and close to 100 dierent PTKs encoded by the human genome (see paper in this issue by Robinson, 2000) . X-ray crystallographic structures of some PTKs have been determined (e.g. Zhang et al., 1994; Hubbard et al., 1994; Mohammadi et al., 1996; Xu et al., 1997; Sicheri et al., 1997) . Numerous small molecule inhibitors for various PTKs have been developed in the last 5 years. Some of these drugs are already undergoing clinical trials with promising results (Druker and Lydon, 2000) . These compounds, in addition to being used as potential drugs for treating various diseases, are extremely useful as reagents to study the mechanism of action of PTKs and their role in signal transduction pathways. In this mini-review, we shall give a brief overview on the role of PTKs on cancer and some other diseases, and why they are important as drug targets. General approaches to the development of inhibitors will then be discussed, followed by a short account on the development of pseudo-substrate-based peptide inhibitors for PTK. The development of small molecule inhibitors and the results of recent pre-clinical and clinical studies will be emphasized. Recently several reviews were written about this topic and interested readers can consult those reviews for further details (Al-Obeidi et al., 1998; Boschelli, 1999; Cohen, 1999; Levitzki, 1999; . In addition there is a very informative web site on`Protein Kinase Resource' (www.sdsc.edu/Kinases/) that lists many diseases that associate with protein kinases. Although the focus of this mini-review is on PTK inhibitors, the general principle also applies to inhibitors for protein serine/ threonine kinases.
Protein tyrosine kinases as a drug target
PTKs play a crucial role in many cell regulatory processes such as mitogenesis, dierentiation and development, oncogenesis, angiogenesis, cell survival and apoptosis, cell shape and adhesion, cell cycle control, growth control, T-cell and B-cell activation, responses to extracellular stimuli, neurotransmitter signaling, platelet activation, transcription control, and glucose uptake (Hunter 1997; Patarca 1996) . Functional perturbation in PTKs or protein-tyrosine phosphatases may result in many common diseases such as cancer, immunode®ciency, diabetes, atherosclerosis, and psoriasis.
Many PTKs have been implicated in human cancer (Hunter 1997; Kolibaba and Druker 1997) . These include the overexpression or ampli®cation of EGFR in glioblastoma, HER2/neu in breast cancer, Axl in myeloid leukemia, Src in colon and breast cancer, and Rse/Sky in breast cancer. In addition to ampli®cation, chromosome translocation or mutation are common in some cancers. In chronic myelomonocytic leukemia, there is a t(5 : 12) translocation (fusion between platelet derived growth factor b (PDGFb) and Tel resulting in receptor dimerization (Golub et al., 1994) . In chronic myelocytic leukemia, there is a t(9 : 21) translocation resulting in a Bcr-Abl fusion protein, a PTK with an oligomerization site at the Bcr domain (Rabbitts, 1994) . In multiple endocrine neoplasia 2A, there is a Cys-634-Arg mutation at the extracellular domain of Ret (GDNF receptor) resulting in dimerization of the receptor (Van Heyningen, 1994) . In papillary renal cell carcinoma, there is a missense mutation at the catalytic domain of Met (HGF receptor) resulting in an increase in catalytic activity (Schmidt et al., 1997) . Inhibitors against these PTKs are believed to have anti-tumor eects against these speci®c cancers. In fact, STI571, a potent and relatively speci®c small molecule inhibitor Oncogene (2000) 19, 5690 ± 5701 ã 2000 Macmillan Publishers Ltd All rights reserved 0950 ± 9232/00 $15.00 www.nature.com/onc *Correspondence: KS Lam against Bcr-Abl PTK has been proven successful in recent clinical trials on chronic myelocytic leukemia patients (Druker and Lydon 2000) . Another approach to anti-cancer therapy is to inhibit angiogenesis . SU5416, a VEGF and FGF PTK inhibitor, has been developed for this purpose, and is currently undergoing Phase I and Phase II clinical trials (O'Donnell et al., 1999) .
Basic ®broblast growth factor (bFGF) and PDGF and their corresponding receptors have been implicated in atherosclerotic plaque formation (Ross, 1993) . Inhibitors against these two receptors may be therapeutic for coronary artery restenosis. TGF-a and/or amphiregulin genes are ampli®ed in psoriasis and results in the activation of EGFR PTK (Elder et al., 1989; Cook et al., 1992; Hashimoto and Yoshikawa, 1992) . A potent PTK inhibitor may be useful for the treatment of this disease. In osteoporosis, a potent Src PTK inhibitor may be therapeutic as Src function is crucial in osteoclastic activity and knockout mice failed to form a`ruing border' and resorb bone (Lowe et al., 1993; Boyce et al., 1992) leading to osteopetrosis (Soriano et al., 1991) .
Approaches to the development of inhibitors

Site of inhibition
PTKs are multi-domain enzymes that include the catalytic domain and other discrete domains such as adapter or signaling domains (e.g. SH2, SH3, or PH domains), and in the case of receptor PTK, the transmembrane domain, and extracellular binding domain. In some of the non-receptor PTK such as Src PTK, there is a myristoylation site at the Nterminus. This myristoylation site is crucial for membrane localization of the enzyme. Inhibition of the function of any of the above domains may impair cell signaling pathway of which PTK is a critical component. There have been enormous eorts in the pharmaceutical industry and academia to develop inhibitors against the above mentioned domains of various PTK. So far the most successful compounds are those that target the Mg-ATP complex binding site of the catalytic domain of the enzymes. Limited number of successful compounds that target the sites other than the catalytic domain of PTK have been developed. For example, Herceptin, a monoclonal antibody against the extracellular domain of Her-2/ neu (Baselga et al., 1996; Stebbing et al., 2000) , had been approved for use in Her-2 positive breast cancer patients. AP22408, an osteoclast-selective, non-peptide SH2 domain inhibitor that has in vivo anti-resorptive activity in the rat model is currently being developed for the treatment of osteoporosis (Shakespeare et al., 2000) .
Lead identification and optimization
Most small molecule kinase catalytic domain inhibitors were initially identi®ed by random screening of compound libraries for speci®c protein kinase inhibitory activities. These compound libraries include sources from natural products or synthetic compound collections. Combinatorial library methods have now played an increasing role in both the identi®cation of the initial lead, and subsequent optimization of the lead compounds (Lam, 1997; Floyd et al., 1999) . In the last 5 years, several highly sensitive accurate and reliable high-throughput assays have been developed for screening for protein kinases inhibitors. In the scintillation proximity assay (Parker et al., 1997) . In the¯uorescence polarization assay (Seethala and Menzel, 1997) , the incubation mixture includes a¯uorescence-labeled peptide substrate, Mg-ATP, protein kinase, and antiphosphotyrosine antibody. Upon phosphorylation, thē uorescence-labeled peptide substrate will bind to the anti-phosphotyrosine antibody, resulting in a slow rotation of the bound¯uorescence-labeled phosphopeptide and the detection of the polarized light. In the presence of protein kinase inhibitor, the light becomes depolarized. In the heterogeneous time-resolved dissociation-enhanced¯uorescence technology , synthetic substrate is ®rst coated onto the multi-titer plate. Europium chelate-labeled anti-phosphotyrosine antibody is used to detect phosphotyrosyl peptide with the absence of background¯uorescent signal. This is a heterogeneous assay and requires plate washing. The homogenous time-resolved¯uorescence assay (Parker et al., 1997) , on the other hand, do not require plate washing. This method is based on¯uorescence resonance energy transfer between two¯uorescent labels, the europium cryptate labeled anti-phosphotyrosine antibody serves as the energy donor, and allophycocyanin-labeled streptavidin serves as an energy acceptor. Upon phosphorylation, the biotinylated peptide substrate will bring the europium cryptate and allophycocyanin in close proximity, resulting in the generation of a timeresolved¯uorescent signal.
With the increasing number of X-ray crystallographic structures available for various protein kinases (www.sdsc.edu/Kinases/) and the advances in structured-based drug design, computational chemistry has now become indispensable in the development of protein kinase inhibitors. Recently the molecular modeling and structure-based design of ATP-site directed protein kinase inhibitors was reviewed (Toledo et al., 1999) . Several models were built based on X-ray data of enzymes co-crystallized with or without inhibitors, and homology modeling. These models were used to explain the SAR results of various classes of PTK inhibitors. In a recent publication a pharmacophore model was used to design EGFR PTK inhibitors (Traxler et al., 1999) . Based on this model compounds 1 and 2 ( Figure 1 ) were synthesized. Compound 1 had an IC 50 of 0.095 mM for EGFR in in vitro testing with good selectivity with respect to v-Abl (20 mM), Src (4100 mM) and PKC-a (4100 mM) enzymes. Furthermore, compound 2 was about 10 times more potent than compound 1 with comparable selectivity. Both compound 1 and 2 were more active than genistein and avopiridol ( Figure 1 ) which were used in construction of the pharmacophore model. Compound libraries were designed to target speci®cally ATP-cofactorbinding site in protein kinases by combining knowledge-and diversity-based components (Stahura et al., 1999) . This study led to the proposal of 75 potential hetrocyclic scaolds that can mimic purine ring in ATP cofactor. Successful application of some of these scaolds for actual library synthesis and testing remained to be seen. As indicated above, most of the small molecule inhibitors developed so far bind to the Mg-ATP complex binding pocket. Despite close sequence homology among most PTKs at the ATP binding site, it is surprising that many small molecule inhibitors reported are rather potent and highly speci®c to a particular PTK. Clinical trials of some of these compounds have not revealed any signi®cant acute side eects. This however does not mean that all these inhibitors are safe and speci®c. There are numerous enzymes in a mammalian cell that require ATP as a substrate. Serious side eects due to prolonged use (e.g. in osteoporosis patients) of inhibitors that cross-react with a number of other ATP requiring enzymes is still a concern. The catalytic domain of protein kinase has a deep pocket for ATP and a more¯exible groove for the protein or peptide substrate. This is perhaps the reason why most compounds identi®ed from random screening for protein kinase inhibitory activity bind to the ATP binding site. Except for the pseudo-substrate based peptide inhibitors (Al-Obeidi et al., 1998; AlfaroLopez et al., 1998) , very little work has been done on the development of inhibitors that compete at the protein or peptide substrate binding site.
Peptide inhibitors
We have recently reviewed the literature on the peptide substrates for PTKs (Al-Obeidi et al., 1998) . The substrate recognition motif for protein serine/threonine kinases can generally be de®ned by a linear motif, e.g. RRXS for protein kinase A. For some unknown reason, substrate motifs for PTK are harder to de®ne. Synthetic peptides derived from autophosphorylation sites or phosphorylation sites of protein substrates are often poor substrates for PTK. Using various combinatorial peptide library approaches, we and others (Lam et al., 1995; Songyang et al., 1995; Lou et al., 1996; Wu et al., 1997 Wu et al., , 1998 Schmitz et al., 1996) were successful in identifying some relatively potent peptide substrates for a number of PTKs. For example, YIYGSFK, GIYWHHY, and EEIYGEFF for Src PTK have Kms ranging between 25 ± 55 mM.
Based on the peptide substrate LRRASLG, Feramisco and Krebs (1978) developed a relatively potent inhibitor for PKA by replacing the Ser residue with Ala. Walsh and Glass (1991) summarized their data on a large number of pseudosubstrate-based peptide inhibitors for PKA. Ki for these peptides varies between 0.004 ± 150 mM. The longer peptides (e.g. 17 amino acid long) are generally more potent. The smallest and most active peptide inhibitor is a nonapeptide, GRTGRRNAI, with a Ki value of 0.036 mM. We (Wu et al., 1996; Lou et al., 1997; Alfaro-Lopez et al., 1998) and others (Fry et al., 1994; Niu and Lawrence 1997a, b; Walsh and Glass 1991; Petrakis and Nagabhushan 1987; Burke et al., 1993; Yuan et al., 1990) have applied the same strategy to Figure 1 Chemical structures of natural products and their derivatives with kinases inhibitory activity develop pseudosubstrate-based peptide inhibitors for PTK. The following Tyr analogues have been used to replace Tyr in these studies: p-¯uorophenylalanine, pchlorophenylalanine, 1-naphthylalanine, 2-naphthylalanine, phenylalanine, D-tyrosine, methyl-tyrosine, 1,6-dichloro-tyrosine, tetra¯uorotyrosine, 4-phosphonophenylalanine, phosphomethyl-phenylalanine, tetrauorotyrosine,
, 3-iodotyrosine, penta¯uoro-phenylalanine, and p-guanidino-phenylalanine. The result of these studies have been recently reviewed (Al-Obeidi et al., 1998) and will not be repeated here. Some relatively potent peptide inhibitors reported for Src PTK are shown in Table  1 . In general, certain tyrosine analogues may work well for some peptides and for some PTKs but not for others. Most of these peptides are incapable of entering intact cells, where the catalytic domain of PTK is. Therefore they generally are not useful therapeutically. However, they can serve as important reagents to study the mechanism of action of the enzyme, to map the pharmacophores of the substrate binding pocket, and to be used as leads for the design of peptidomimetic inhibitors. Natural products and related derivatives (Figure 1) The ®rst reported small molecule inhibitors of EGFR were natural product¯avones and iso¯avones such as quercetin (Glossmann et al., 1981) and genistein (Akiyama et al., 1987) , which were weak and nonselective competitive inhibitors for ATP. Other natural products such as the indolecarbazole staurosporine (Ruggeri and Burgess, 1989) , lavendustin (Onoda et al., 1989) and erbastatin (Umezawa et al., 1986) were also weak and nonselective EGF-R inhibitors. Through screening of the fermentation broth, benzoquinoid macrolidic fungal metabolites produced by Clitocyte clavips, clavilactones CA, CB and CD were isolated and characterized (Cassinelli et al., 2000) . These Clavilactones were active against Ret/ptc1 and EGFR PTKs, and with minimal eects on v-Abl TK and p34 (cdc2) serine/threonine kinase (IC 50 2.8, 5.5, 81.3, and 128 mM respectively for the most active compound, CD). CB was shown to be a non-competitive inhibitor of EGFR with respect to ATP or substrate poly-E6A3Y. CD also inhibited the growth of A431 cells, which overexpress active EGFR in contrary to IGROV-1 and SKOV-3 cells, which express low population of the receptor. EGF-induced receptor autophosphorylation was inhibited by CB, CD and their semisynthetic analogs. These Clavilactones represent a new structural class of PTK inhibitors.
Small molecule kinase catalytic domain inhibitors
Staurosporine is important as a prototype PTK inhibitor since it was initially used in the study of kinases inhibitors as a non-selective ATP-competitive inhibitor. Recently a related class of indolecarbazole alkaloid K-252a was isolated from the culture broth of Nocardiopsis species. This class of compounds and their analogs were recognized to be eective inhibitors for PTKs involved in neurotrophin receptors activation. K-252a inhibits PKC at IC 50 =28 nM, cyclic AMP dependent protein kinase (PKA) IC 50 =16 nM. It was shown that K-252a inhibited PKC through competitive interaction at the ATP-binding pocket (Kase et al., 1987) . Development of other analogs of K-252 was recently reviewed (Ruggeri et al., 1999) . Anti-tumor ecacy of CEP-701 and CEP-751 were studied in several pre-clinical xenograft models of human pancreatic ductal carcinoma (PDAC). CEP-701 was administered at 10 mg/kg subcutaneously at twice a day dosing for periods of 3 to 4 weeks in six human xenograft models of PDAC. It was shown that CEP-701 could inhibit the growth of some models of tumors by up to 70%. These results will encourage further clinical study of these compounds. UCN-01 is a protein kinase antagonist studied in vivo in A498 renal carcinoma xenografts and showed good ecacy (Sausville et al., 1998) . In human testing the drug showed a dierent pharmacokinetic behavior due to plasma protein binding and further study was needed.
Quercetin inhibits tyrosine kinases, protein kinase C, and phosphatidyl inositol-3 kinase and has antiproliferative activity in vitro and in vivo. Phase I clinical trial indicated that this compound given at short i.v. infusion at 3-week intervals and weekly intervals is tolerable and the dose limiting toxicity is nephrotoxicity. In nine of the 11 patients in the study, lymphocyte protein tyrosine phosphorylation was inhibited from 1 ± 16 h after administration of the drug. Serum cancer markers for two patients with ovarian cancer and one 
Lou et al., 1997 GI(2')D-Nal-WHH-(2')D-Nal 4.0 GI(2')Nal-WHH-(2')Nal 4.2 GI-(2')Nal-WHH-Aba 7.0 GI-(2')D-Nal-WHHY 16 GI-(2')Nal-WHHY 23 GI-(2')Nal-WHH 26 GI-(2')D-Nal-WHH 26
c[Pen-C] represents cyclization of peptide with disul®de bond between penicillamine and cysteine; Nal: naphthylalanine; Aba: Aminobenzoic acid; Pen: penicillamine; (3,5-diI)Tyr: 3,5-di-iodo-Tyrosine; (3-I)Tyr: 3-iodo-Tyrosine patient with hepatoma fell as a result of the treatment (Ferry et al., 1996) .
Quinazolines, pyridopyrimidines and related heterocyles (Figure 2) The pro®le of quinazolines and its application in designing inhibitors against EGFR family of tyrosine kinases was recently reviewed (Klohs et al., 1997; ). 4-Anilinoquinazolines are potent selective inhibitors of EGFR PTK by competing at the ATP binding site Garcia et al., 1993) . Highly potent and selective inhibitors were developed when the molecule was substituted with electron donating groups at positions 6 and 7 together with a lipophilic group at 3' Ward et al., 1994) . Further structure-activity (SAR) study showed that incorporation of electron donating heterocyclic ring at positions 6 and 7 resulted in a potent inhibitors with good selectivity for EGFR PTK activity . Expanding the bicyclic quinazolin inhibitors into tricyclic derivatives resulted in the discovery of imidazolo-, pyrazolo-and pyrroloquinazolines derivatives. As with bicyclics, structure modi®cation results in compounds having IC 50 values in the pM range against the isolated enzyme and low nM for inhibition of EGF-mediated receptor autophosphorylation (Palmer et al., 1997; Rewcastle et al., 1996) . However, the poor aqueous solubility of these tricyclic compounds has been problematic. Attempt to enhance the water solubility of the tricyclic quinazolines (e.g. compound 3 and 4) resulted in loss of activity of these inhibitors. Further SAR works on quinazolines motif resulted in the synthesis of 6-substituted analogs of 4-(Phenylamino) pyrimido[3,4-d]pyrimidines compounds PD 0165557 (Rewcastle et al., 1998) with good water solubility is an example of this family. This compound had an enzyme IC 50 of 0.65 nM and a cellular IC 50 of 8 nM. This compound was examined in several tumor models, by oral, intraperitoneal, and subcutaneous routes. A 100% growth inhibition of a non-small cell lung cancer cell line (AH125) was achieved at an oral dosing of 80 mg/ kg. At 25 mg/kg twice a day intraperitoneal dosing, there was a 120% delay in tumor growth in the MCF-7 breast cancer Xenograft model. Despite the high potency and prolonged inhibition of EGFR function reported for some 4-anilinoquinazoline Figure 2 Chemical structures of quinazolines and their analogs heterocycles with kinases inhibitory activity reversible inhibitors, the high intracellular concentrations of ATP make it dicult to reach suciently high concentrations in vivo to completely block EGFstimulated signal transduction for long periods. Recently several reports on using irreversible inhibitors to block EGFR TK activity for a long enough period were starting to appear (Smaill et al., 1999) . In this approach a high anity reversible inhibitors were converted into irreversible inhibitors by alkylating the Cys 773 residue on the edge of the ATP binding pocket. It was observed that the presence of acrylamide in position 6 of quinazoline scaold gave better inhibitor than its 7 analog because Cys 773 sulfhydryl group was 4A closer to the acrylate to form the required Michael adduct. From the several irreversible inhibitors that were tested, compound PD0183805 gave good results in several EGFR model A431 cells with IC 50 7.4 nM. In murine A431 xenograft model, PD0183805 showed more than 80% inhibition of tyrosine phosphorylation for a period more than 72 h following a single oral dose.
In a recent study ) AG1517 and AG1478 were tested to inhibit psoriatic keratinocytes. The study demonstrated that both AG1517 and AG1478 were highly potent and selective EGFR kinase inhibitors and both compounds could be valuable therapeutic agents in diseases where EGFR plays a prominent part, such as psoriasis. AG1478 was also shown to enhance the sensitivity of non-small cell lung cancer cell lines to other chemotherapeutic drugs like cisplatin and doxorubicin (Lei et al., 1999) . In a rat model of pulmonary ®brosis caused by intratracheal instillation of vanadium pentoxide (V 2 O 5 ), AG1478 showed a 50 ± 60% decrease in V 2 O 5 -stimulated hydroxyproline accumulation (Rice et al., 1999) . This action of AG1478 was attributed to its EGFR PTK inhibition. CP358774 was tested in HN5 head and neck tumor cells and showed good selectivity toward EGFR PTK in both in vitro and in vivo models (Iwata et al., 1997) . Another quinazoline compound reported to be in clinical trial is ZD1839 (Woodburn et al., 1997) . In nude mice, this drug was well tolerated up to 4 months.
A series of 4-(phenylamino) pyrrolopyrimidines has been recently reported (Traxler et al., 1996) . These compounds were competitive for ATP and inhibited the EGFR tyrosine kinase with IC 50 as low as 4 nM and without activity against other kinases like Src or PKA. CGP 59326 was selected for further studies. CGP 59326 was showed to inhibit the growth rate of A431 xenografts by 50% with oral doses in the range of 10 and 20 mg/kg/day. Combination of CGP59326 with cytotoxic agents resulted in tumor regression and cures in some animals (Lydon et al., 1998) . Recently, several inhibitors for Src kinase were reported. One class of 4-anilino-3-cyano-6,7-dimethoxyquinolines were found to be good inhibitors for Src kinase (Ye et al., 2000) . Compound 6 was active at IC 50 of 6.2 mM.
Phenylamino-pyrimidines (Figure 3)
A special class of compounds containing a (phenylamino) pyrimidine moiety in their structure such as CGP53716 and CGP57148 (currently called STI 571) were discovered to be potent kinase inhibitors by competing with ATP for binding at the catalytic domain of c-Abl, PDGF and c-Kit receptor PTK (Buchdunger et al., 1995 Druker et al., 1996) . STI 571 is particularly interesting as it has recently proven to be eective clinically in chronic myelocytic leukemia patients (Druker and Lydon 2000) . In preclinical studies, this drug inhibited autophosphorylation of v-Abl, PDGF receptor, and c-Kit receptor at submicromolar concentration (0.1 mM). It also blocked PDGF-induced inositol phosphate formation, MAP kinase activation, and c-fos mRNA expression in intact cells. In addition, it inhibited proliferation of Bcr-Abl expressing cells both in vitro and in vivo. Given at three times a day over an 11-day period, 87 ± 100% of the Bcr-Abl tumor-bearing mice were cured of the disease. In a phase I/II study, STI 571 was given to chronic myelocytic leukemia patients p.o. daily without signi®cant side eects. At doses of 300 mg or greater, all patients have achieved complete hematologic and cytologic responses.
Stem cell factor and its receptor c-Kit represent one of the autocrine growth mechanisms for small cell lung cancer. Over 70% small cell lung cancer contain the ckit receptor. At a concentration of 5 mM, STI-571 was able to inhibit cell motility, decrease intracellular levels of reactive oxygen species, cell growth of three small cell lung cancer cell line . In addition, it also inhibited tyrosine phosphorylation of c-Kit and its in vitro kinase activity.
Benzylidene malononitrile (tyrphostins and their analogues) (Figure 4)
Due to the ease of chemical synthesis of this class of compounds several hundreds were made and tested for their tyrosine kinase inhibitory activity (Levitzki and Gazit, 1995) . Tyrphostins have been shown to be a competitive inhibitor for PTKs at either or both ATP and substrate (polyGAT) binding sites (Posner et al., 1994) . Compound RG13022 has been taken for clinical testing as an eective inhibitor of the growth of normal and psoriatic keratinocytes (Dvir et al., 1991) . Recently RG13022 was evaluated in vivo for its anti-tumor activity (Mcleod et al., 1996) . In this study it was shown that (Z) RG13022 and its isomer (E) RG13022 had no in¯uence on the growth of HN5 tumors when given chronically. The rapid in vivo elimination of RG13022 from the animal has been blamed for lack of in vivo inhibitory activity of these compounds. Thus an improved delivery or structure modi®cations are needed to improve the potency and half-life of RG13022 or other similar compounds. In a recent report dimeric analogs of tyrphostins were synthesized in an attempt to target the activated EGFR that have been dimerized. Several of these compounds were identi®ed as PTK inhibitors. Com- Figure 3 Chemical structures of phenylamino-pyrimidines with kinases inhibitory activity pound AG537 inhibited EGFR PTK with an IC 50 of 0.4 mM. The inhibition was competitive against poly-GAT substrate but noncompetitive against ATP. Full biological data is not yet available. SU1498 is another tyrphostin analog that was tested against Flk-1 PTK and showed an IC 50 of 0.7 mM . Flk-1 is a receptor for vascular endothelial growth factor (VEGF), which has been shown to play a role in angiogenesis and growth of a variety of tumor types (Millauer et al., 1996) . In attempt to develop drugs that inhibit the human papiloma virus 16 (HPV 16) which is considered to cause the cervical cancer, several tyrphostins were evaluated . Because of the enhanced activity of EGFR in the HIV16-immortalized human keratinocytes (HF-1) cells, HF-1 cells were used as a model for the infected genital epithelium the natural host of HPV16 infection. Three groups of tyrphostins were studied on HF-1 cells under various conditions. It was found that some tryphostins like AG81, AG494 and AG1387 and their analogs can induce apoptosis in HF-1 cells without aecting normal keratinocytes. The potential use of these agents for treatment of papilloma was suggested. The potency of inhibiting HF-1 in culture was AG174quinazoli-ne4AG14784AG814 (notice that this compound is derived from natural product lavendustin).
In a recent study, a panel of PTK inhibitors (tryphostins) were tested and compared for antiproliferative actions on the hormone-dependent human breast cancer cell line, MCF-7, in vitro (Twaddle et al., 1999) . The E2-mediated growth stimulation was completely inhibited (cytostatic eects) by the EGFRselective inhibitors A47, B50(+) and their analogs. The potency of these agents was A474B50(+). The eect of AG957, a tryphostin PTK inhibitor, was tested in anti-CD3-stimulated Jurkat T Acute Lymphoblastic Leukemia cells (Losiewicz et al., 1999) . It was found that AG957 at 25 mM produces 90% inhibition of Jurkat T-cell growth. Also it was found that within 4 h of addition of 25 mM concentration of AG957 a complete inhibition of MAPK to respond to anti-CD-3 was achieved.
Genistein is a natural iso¯avone present in soybeans at 1 ± 2 mg/g. The eect of genistein and tryphostin 25 on the growth and motility of human bladder cancer cell lines were compared (Theodorescu et al., 1999) . Cell lines with diverse EGFR and p21ras expression levels were used. In this study, both genistein and tryphostin 25 were eective inhibitors of bladder cancer motility and growth, key factors in the development of muscle invasive disease. Also, the inhibitory eects of these agents were more profound in cells that overexpress EGFR. Cells that had a mutant p21ras but didn't overexpress EGFR were inhibited much less by these two compounds.
SU101 is a PDGF PTK inhibitor which was tested in patients with advanced solid malignancies (Eckhardt et al., 1999) . The results of this phase I study demonstrated good toxicity and pharmacokinetics pro®les for SU101 with cytostatic eect in-patients with neoplasms in which aberrant cellular proliferation is mediated by PDGF-dependent pathways. It was observed that Figure 4 Chemical structures of benzylidene malonates (tryphostins) and their analogs with kinases inhibitory activity SU101 converted in vivo to its major metabolites SU0020 rapidly. The mechanism of action of SU0020 was found to be via pyrimidine synthesis by inhibiting dihydroorotate dehydrogenase (Xu et al., 1996) .
Indoles and oxindoles (Figure 5)
Several PTK inhibitors were found to contain indole moiety in their structure. Chemical library screening of more than 100 000 compounds against PTK led to the discovery of PD146568. This compound showed selectivity toward EGFR PTK. An extensive SAR study of this family showed that these inhibitors inhibited both EGFR and Src PTK (Palmer et al., 1995) . This class of compounds has low micromolar inhibitory activity both against isolated enzyme and in whole cell bioassays. The mechanism of action of these compounds was shown to be noncompetitive against ATP or peptide substrate. Based on thiol reversal studies a thiol-disul®de exchange with a thiol-containing residue within the catalytic site of the PTK enzyme was proposed. In attempt to enhance the potency and selectivity of this family of inhibitors, compounds with Se replacing S were synthesised and tested (Palmer et al., 1995) . The Se-containing compounds (e.g. like compound 7) were more potent (about 10-fold) than the S-congeners (e.g. PD146468). Compound 7 showed IC 50 of 0.9 mM against EGFR PTK while the S-analog had only 7.4 mM in the same assay. Both Se-and S-compounds were tested in vivo against a panel of tumor models, including the A431 epidermal and C6 glioma human tumor xenografts. Neither compound showed any antitumor activity in a 7-day continuous infusion study. The results from mechanistic studies showed that much of the anity of these compounds for the enzyme might come from slow and indiscriminate chemical modi®ca-tion of enzyme thiols. Based on these ®ndings this class of compounds was dropped from further development.
Recently a new class of FGF PTK inhibitors containing oxindole scaold were reported (Mohammadi et al., 1997) . Two compounds, SU4984 and SU5402 from this class inhibited kinase activity of FGF with a median IC 50 of 10 ± 20 mM in the presence of 1 mM adenosine triphosphate (ATP) when tested in vitro for autophosphorylation inhibition of the puri®ed kinase domain of FGFR1. In contrast to SU4984, SU5402 did not inhibit tyrosine phosphorylation of IR and only weakly inhibited phosphorylation of PDGFR. Neither compound inhibited the kinase activity of EGFR, even at concentrations as high as 200 mM. Several compounds were synthesized based on 3-substituted indolin-2-ones and evaluated for their potential application as an inhibitor for VEGF and FGF PTKs (Sun et al., 1998 . The use of these oxoindole based compounds and their analogs in inhibition of tumor angiogenesis was reviewed recently . To identify compounds with speci®city in antagonizing of the Flk-1 kinase, hundreds of oxoindole based analogs were subjected to panel of bioassays. These include several potent and speci®c inhibitory activity in whole-cell RTK assays as well as growth assays with human umbilical vein endothelial cells (HUVECs) (Sun et al., 1998) . SU5416 was identi®ed as a good candidate for further clinical evaluation (Fong et al., 1999) . In preclinical trial SU5416 was administered twice weekly at 50 mg/kg to mice bearing subcutaneous xenografts resulted in 77% inhibition of tumor growth (Fong et al., 1999) . In recent communication SU5416 was advanced into phase I clinical trial with good tolerance in patient received SU5416 twice weekly (O'Donnell et al., 1999) .
In an attempt to develop non-ATP competitive inhibitors a family of compounds based on hydroxyindoles were designed, synthesized and tested against Src PTK (Milkiewicz et al., 2000) . Compound 8 was tested and found to have an IC 50 of 38 mM for Src PTK. 
Anti-receptor antibody
Chimeric antibody C225 binds to EGFR and inhibits growth of cancer cells expressing the receptor. It retards or arrests cell cycle progression at G1 phase. The mechanism of growth inhibition involves increased levels of p27KIP1 and inhibition of cyclindependent kinase-2 activity (Mendelsohn, 1997) . Three phase I trials of this antibody with or without cisplatin showed that C225 has dose-dependent pharmacokinetics, and doses that achieved saturation of systemic clearance were well tolerated. Some patients experienced disease stabilization, and two patients with partial responses were observed (Baselga et al., 2000) .
Herceptin, a recombinant humanized monoclonal antibody, has high anity for p185HER2 and inhibits the growth of breast cancer cells that overexpress HER2. Early clinical trial (Baselga et al., 1996) demonstrated that the drug is safe and eective. The drug had been approved by the FDA for the treatment of breast cancer patients with HER2 positive tumor. Clinical trials have now been extended to other tumor types that overexpress HER2. The major side eect of this drug is cardiotoxicity when given in conjunction with doxorubicin (Stebbing et al., 2000) .
A Phase I study using anti-CD19 monoclonal antibody-genistein immunoconjugate (B43-Genistein) was performed on 15 acute lymphoblastic leukemia patients and one chronic lymphocytic leukemia patient Chen et al., 1999) . This drug is unique as it combines both an antibody that targets the extracellular domain of a receptor (CD19), and a small molecule natural product that targets the catalytic domain of a PTK to form an antibody-drug conjugate. The drug was well-tolerated, and there was one patient with durable complete remission and two patients with transient responses. Moderate levels of human antimouse antibody (HAMA) were detected in three of the nine patients examined.
SH 2 domain inhibitor (Figure 6)
Since Src SH 2 domain is intracellular, the drug has to enter the cell in order to be able to inhibit the enzyme. Thus far, most Src SH 2 inhibitors are phosphopeptides (Sawyer, 1998) or peptidomimetics (Lunney, 1997a,b) that incorporate phosphotyrosine or phosphotyrosine-like mimics. Phosphotyrosine can be degraded by phosphatases and has poor transport properties. Many metabolically stable phosphotyrosine analogs have been tried but binding anity of ligands using these analogs are generally low (Bot®eld and Green 1995). Shakespeare et al. (2000) recently reported the use of computational chemistry to design an osteoclast-selective, nonpeptide SH 2 inhibitor that has in vivo antiresorptive activity. The drug, AP22408, uses 3',4'-diphosonophenylalanine as a phosphotyrosine mimic (Figure 6 ). In addition to forming an important pharmacophore for the SH 2 domain, the 3',4'-diphosphonophenyl group is able to bind to bone, thus concentrating the drug at the bone surface where osteoclasts, the target cells, are located. AP22408 inhibited Src SH 2 -ligand binding with an IC 50 of 0.3 mM. In an in vitro rabbit osteoclastmediated resorption assay, the drug has an IC 50 of 57 mM. In an in vivo antiresorptive rat model, the drug is active when the animals were dosed at 50 mg/kg twice daily.
In a recent study (Lee and Lawrence, 2000) combinatorial library of 900 members was used to discover compound 9 (Figure 6 ). Compound 9 had an IC 50 of 1.2 mM against Lck SH 2 domain. Compound 9 is nearly as potent an Lck SH 2 ligand as its Ac-pYEEI-NH 2 peptide counterpart (IC 50 =0.66 mM). The coumarin-containing 9 is a 37-fold more potent SH 2 ligand than the corresponding acetylated derivative. In addition the 3-methyl-2-pyrazolin-5-one-derivatized moiety furnishes a 16-fold enhancement relative to acetyl substituent. This study demonstrated that a combinatorial approach can be used to replace the tripeptide EEI with non-peptide mimics with retention of activity for SH 2 domain.
Conclusions
PTKs (as well as serine and threonine kinases) are crucial enzymes in many cell signalling pathways and are altered or overexpressed in many disease states. Inhibitors against some of these enzymes may be useful for the treatment of a number of diseases. In the last decade, large numbers of PTK inhibitors have been developed. Although the majority of these compounds are directed against the catalytic domain, some drugs are targeting the rest of the enzyme molecule such as the extracellular domain and the SH 2 domain. Several of these compounds have already been in or currently undergoing clinical trial. The fact that STI 571, a Bcr-Abl PTK inhibitor, can induce complete remission in most of the patients in a Phase I/II clinical trial for chronic myelocytic leukemia exempli®es the enormous clinical potential for this class of drug. Although clinical responses to some PTK inhibitors as a single agent have been observed in several clinical trials, there is evidence that some of these inhibitors are more eective if given concurrently or sequentially with chemotherapy such as taxol, carboplatin, cisplatin, and etoposide (Woodburn et al., 2000; Lydon et al., 1998; Baselga et al., 1998 ; Figure 6 Chemical structures of SH2 domain inhibitors Pietras et al., 1998; Pegram et al., 1999; Demidem et al., 1997; Wen et al., 2000; Ciardiello et al., 2000) . It is likely that several clinically useful PTK inhibitors will be in the market within the next decade, and that these new therapies will be more eective and with fewer side eects on patients with cancer or other diseases.
